{"organizations": [], "uuid": "88099271d936a7d6b0aa8c8129f4cab30bc8b63c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "in.reuters.com", "main_image": "https://s3.reutersmedia.net/resources/r/?m=02&d=20180402&t=2&i=1247374728&w=1200&r=LYNXNPEE3115K", "site_section": "http://feeds.reuters.com/reuters/INhealth\r", "section_title": "Reuters: Health", "url": "https://in.reuters.com/article/us-allergan-restructuring/allergan-plans-options-for-womens-health-unit-bloomberg-idINKCN1H91TE", "country": "US", "domain_rank": 408, "title": "Allergan plans options for women's health unit: Bloomberg", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-02T23:10:00.000+03:00", "replies_count": 0, "uuid": "88099271d936a7d6b0aa8c8129f4cab30bc8b63c"}, "author": "", "url": "https://in.reuters.com/article/us-allergan-restructuring/allergan-plans-options-for-womens-health-unit-bloomberg-idINKCN1H91TE", "ord_in_thread": 0, "title": "Allergan plans options for women's health unit: Bloomberg", "locations": [], "entities": {"persons": [{"name": "akankshita mukhopadhyay", "sentiment": "none"}, {"name": "shounak dasgupta", "sentiment": "none"}], "locations": [{"name": "singapore", "sentiment": "none"}, {"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "allergan", "sentiment": "negative"}, {"name": "bloomberg", "sentiment": "negative"}, {"name": "allergan plc", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 2, 2018 / 8:08 PM / Updated 23 minutes ago Allergan seeks options for women's health unit: Bloomberg Reuters Staff 1 Min Read \n(Reuters) - Allergan Plc is considering options for its women’s health unit, including a sale, Bloomberg reported on Monday, citing people with knowledge of the matter. FILE PHOTO: The Allergan logo is seen in this photo illustration in Singapore November 23, 2015. REUTERS/Thomas White/File Photo \nA sale, which would likely attract interest from private equity firms, could value the business at more than $5 billion, according to the Bloomberg report. \nThe women’s health unit, which makes oral contraceptive pills to menopause treatment, raked in $1.04 billion sales in 2017. \nA decision on whether to pursue a sale hasn’t been made and the Botox maker could choose to keep the business, Bloomberg reported. An Allergan spokeswoman declined to comment. \nThe company’s shares closed at $162.27, and have fallen about 34 percent in the last twelve months. Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Shounak Dasgupta", "external_links": [], "published": "2018-04-02T23:10:00.000+03:00", "crawled": "2018-04-02T23:40:15.019+03:00", "highlightTitle": ""}